Lung Cancer

Small Cell Lung Cancer (SCLC)—An OverviewBookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Small cell lung cancer is a common, particularly deadly form of lung cancer. If you wish to learn more, this authoritative encyclopedic discussion from Medscape should be very useful (written with a physician audience in mind).

.

NCCN Clinical Practice Guidelines in Oncology: 2020 UpdatesBookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

The National Comprehensive Cancer Network (NCCN) recently made key updates to its clinical practice guidelines. This news story provides a summary of the updates.

Go to full news story published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer CareBookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

The drug osimertinib (brand name Tagrisso) is beneficial as an adjuvant therapy—treatment given in addition to tumor-removal surgery—for patients with stage IB–IIIA non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Frontline Atezolizumab for PD-L1–High NSCLCBookmark

Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:

The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.

Go to full article published by OncLive.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA OKs Liquid Biopsy to Identify EGFR-Positive Lung CancerBookmark

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved a liquid biopsy test (a type of biopsy that uses a blood draw instead of surgery) for detecting whether patients have EGFR mutations in their metastatic lung tumors, which could help guide treatment options.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant TestBookmark

Excerpt:

“New data this week has added evidence for the value of blood-based cancer testing in non-small cell lung cancer, demonstrating in a cohort of about 300 that comprehensive liquid biopsy — in this case Guardant Health’s Guardant360 test — can help identify targeted mutations in more patients than tissue sequencing.

“The study also found that patients treated on the basis of blood-based test results respond to treatment similarly to those treated based on tissue test results.”

Go to full article published by GenomeWeb on Oct 12, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Study Describes Design, Validation of Foundation Medicine’s Blood-Based TMB TestBookmark

Excerpt from GenomeWeb:

“Researchers from Genentech, Foundation Medicine, UC Davis, and other medical centers, have published a report on the development and early validation of Foundation’s planned blood-based tumor mutational burden test.

“Appearing today in Nature Medicine, the study describes the development of the test and its characteristics, and its retrospective validation in two cohorts. Investigators demonstrated, by applying the assay to samples from two clinical trials, that blood-based TMB (bTMB) could reproducibly identify lung cancer patients who respond to immunotherapy treatment with Roche/Genentech’s atezolizumab (Tecentriq).”

Go to full article published by GenomeWeb on Aug 4, 2018 (Free registration required).

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Lung cancer at ASCO20 VirtualBookmark

Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

This year’s virtual meeting of the American Society of Clinical Oncology featured presentations on several different targeted therapies that appear to provide improved outcomes for lung cancer patients.

Go to full research highlight published by Nature Reviews Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Regional Delivery of Mesothelin-Targeted CAR T-Cell Therapy Creates a Win for Solid TumorsBookmark

Excerpt:

“In patients with malignant pleural disease, autologous mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy demonstrated clinical benefit with no significant toxicity, outcomes that may be due to the regional delivery of the CAR T cells to the intrapleural cavity rather than conventional systemic delivery. The phase I trial (ClinicalTrials.gov identifier: NCT02414269) results were presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting, held March 29–April 3 in Atlanta, Georgia (abstract CT036).”

Go to full article published by Cancer Network on April 10, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Aggressive RT, Surgery Doubles OS in NSCLC With Limited MetsBookmark

Excerpt:

“Aggressive local consolidation in stage IV non-small lung cancer (NSCLC) drastically improved overall survival over standard care in patients with up to three metastatic lesions, a small randomized study found.

“Among 49 patients whose disease had not progressed after initial systemic therapy, overall survival was 41.2 months in those treated with radiotherapy or surgery compared with 17.0 months in those on standard maintenance therapy (P=0.017), reported Daniel Gomez, MD, of MD Anderson Cancer Center in Houston, at a press briefing here at the American Society for Radiation Oncology (ASTRO) meeting.”

Go to full article published by MedPage Today on Oct 22, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pembrolizumab Plus Chemotherapy Prolongs OS, PFS for Metastatic Lung CancerBookmark

Excerpt from Healio:

“The addition of pembrolizumab to chemotherapy extended OS and PFS compared with chemotherapy alone among patients with metastatic, squamous, non-small-cell lung cancer, according to results of the randomized phase 3 KEYNOTE-407 trial presented at International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.

“The double-blind study included 559 treatment-naive patients with metastatic, squamous NSCLC. Patients who had symptomatic central nervous system metastases, a history of noninfectious pneumonitis that required the use of glucocorticoids, active autoimmune disease or who were receiving systemic immunosuppressive treatment were excluded.”

Go to full article published by Healio on Oct 1, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Repotrectinib Shows Promising Activity in ROS1+ NSCLCBookmark

Excerpt from OncLive:

“Repotrectinib (TPX-0005) demonstrated a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC).

“Overall response rates (ORRs) were 80% for tyrosine kinase inhibitor (TKI)-naïve patients (95% CI, 44-97) and 18% for TKI-refractory patients (95% CI, 4-44), including 33% for those who received a dose of 160 mg once daily, according to findings from the ongoing phase I/II TRIDENT-1 study. Interim analysis results were presented at the 19th World Conference on Lung Cancer (WCLC).”

Go to full article published by OncLive on Sep 24, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pediatric Cancer: The “Day One Talk”Bookmark

Article from the Journal of Clinical Oncology, curated by Cancer Commons founder Marty Tenenbaum, PhD.

This piece discusses a “method of delivering bad news to parents of children with cancer in hopes that our approach may be helpful to others and may spur discussion.”

.

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO GuidelineBookmark

Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

There has been confusion about how to conduct follow-up for a patient with lung cancer who has received therapy intended to cure. This new guideline intends to clarify best practice.

Go to full paper published in the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

What Have I Learned in More Than Half a Century in Cancer Medicine?Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Clinical Trials Gone VirtualBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

These Underlying Conditions Make Coronavirus More Severe, and They’re Surprisingly CommonBookmark

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.